End-of-day quote
Shanghai S.E.
23:00:00 20/05/2024 BST
|
5-day change
|
1st Jan Change
|
8.92
CNY
|
-3.98%
|
|
-15.77%
|
+24.93%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,112
|
6,346
|
8,248
|
6,593
|
6,418
|
6,361
|
Enterprise Value (EV)
1 |
5,654
|
7,245
|
9,780
|
8,687
|
8,582
|
8,438
|
P/E ratio
|
30.2
x
|
51.5
x
|
37.5
x
|
83.2
x
|
48.4
x
|
25.5
x
|
Yield
|
0.53%
|
0.62%
|
0.59%
|
0.67%
|
0.69%
|
1.26%
|
Capitalization / Revenue
|
1.54
x
|
1.7
x
|
1.96
x
|
1.35
x
|
1.14
x
|
1.03
x
|
EV / Revenue
|
1.7
x
|
1.94
x
|
2.33
x
|
1.78
x
|
1.53
x
|
1.37
x
|
EV / EBITDA
|
17.8
x
|
21.9
x
|
27.6
x
|
19.8
x
|
15.8
x
|
13
x
|
EV / FCF
|
-6.6
x
|
-15.3
x
|
-13.9
x
|
-20.7
x
|
-222
x
|
-145
x
|
FCF Yield
|
-15.2%
|
-6.55%
|
-7.18%
|
-4.84%
|
-0.45%
|
-0.69%
|
Price to Book
|
1.75
x
|
2.1
x
|
2.57
x
|
2.03
x
|
1.92
x
|
1.77
x
|
Nbr of stocks (in thousands)
|
880,230
|
880,230
|
880,230
|
880,261
|
884,036
|
890,926
|
Reference price
2 |
5.808
|
7.210
|
9.370
|
7.490
|
7.260
|
7.140
|
Announcement Date
|
29/04/19
|
17/04/20
|
16/04/21
|
15/04/22
|
18/04/23
|
22/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
3,330
|
3,733
|
4,205
|
4,891
|
5,621
|
6,147
|
EBITDA
1 |
317.2
|
330.4
|
354.2
|
438.5
|
541.8
|
647
|
EBIT
1 |
159.3
|
143.5
|
111
|
135.8
|
194.1
|
266.1
|
Operating Margin
|
4.78%
|
3.84%
|
2.64%
|
2.78%
|
3.45%
|
4.33%
|
Earnings before Tax (EBT)
1 |
192.3
|
148.8
|
262.2
|
106.3
|
150.1
|
273
|
Net income
1 |
161.4
|
121.3
|
227.9
|
82.69
|
138
|
246.2
|
Net margin
|
4.85%
|
3.25%
|
5.42%
|
1.69%
|
2.46%
|
4%
|
EPS
2 |
0.1923
|
0.1400
|
0.2500
|
0.0900
|
0.1500
|
0.2800
|
Free Cash Flow
1 |
-856.8
|
-474.3
|
-702.6
|
-420
|
-38.63
|
-58.13
|
FCF margin
|
-25.73%
|
-12.71%
|
-16.71%
|
-8.59%
|
-0.69%
|
-0.95%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.0308
|
0.0450
|
0.0550
|
0.0500
|
0.0500
|
0.0900
|
Announcement Date
|
29/04/19
|
17/04/20
|
16/04/21
|
15/04/22
|
18/04/23
|
22/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
542
|
899
|
1,533
|
2,094
|
2,164
|
2,076
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.709
x
|
2.72
x
|
4.326
x
|
4.774
x
|
3.993
x
|
3.209
x
|
Free Cash Flow
1 |
-857
|
-474
|
-703
|
-420
|
-38.6
|
-58.1
|
ROE (net income / shareholders' equity)
|
6.71%
|
4.13%
|
7.15%
|
2.47%
|
4.13%
|
7.09%
|
ROA (Net income/ Total Assets)
|
1.69%
|
1.31%
|
0.97%
|
1.13%
|
1.47%
|
1.9%
|
Assets
1 |
9,540
|
9,234
|
23,587
|
7,337
|
9,416
|
12,972
|
Book Value Per Share
2 |
3.330
|
3.430
|
3.650
|
3.700
|
3.790
|
4.030
|
Cash Flow per Share
2 |
1.140
|
1.030
|
0.7400
|
0.6300
|
0.7800
|
0.8900
|
Capex
1 |
855
|
829
|
703
|
487
|
428
|
338
|
Capex / Sales
|
25.69%
|
22.2%
|
16.72%
|
9.95%
|
7.62%
|
5.5%
|
Announcement Date
|
29/04/19
|
17/04/20
|
16/04/21
|
15/04/22
|
18/04/23
|
22/03/24
|
|
1st Jan change
|
Capi.
|
---|
| +24.93% | 1.15B | | +38.23% | 705B | | +32.82% | 583B | | -3.63% | 364B | | +20.13% | 332B | | +5.10% | 291B | | +16.64% | 238B | | -4.13% | 210B | | +10.63% | 209B | | +8.71% | 169B |
Other Pharmaceuticals
|